504 results about "Heparin" patented technology

The present invention relates methods for treating thyroid cancer, renal cell carcinoma or hepatocellar carcinoma comprising orally administering to a patient in need of such therapy a therapeutic amount of cabozantinib lauryl sulfate salt, preferably in a capsule form. The method allows the administration of the therapeutic amount of cabozantinib lauryl sulfate salt in a fed state or a fasted state and the administration does not exhibit a food effect.

The present invention relates methods for treating thyroid cancer, renal cell carcinoma or hepatocellar carcinoma comprising orally administering to a patient in need of such therapy a therapeutic amount of cabozantinib lauryl sulfate salt, preferably in a capsule form. The method allows the administration of the therapeutic amount of cabozantinib lauryl sulfate salt in a fed state or a fasted state and the administration does not exhibit a food effect.

The invention discloses an epoxy group modified zwitterionic polymer / heparin composite coating and a preparation method thereof. The preparation method comprises the following steps: firstly, constructing an amino-containing adhesion layer on the surface of a substrate by adopting a dip-coating method; then, the substrate is soaked in a mixed solution of the zwitterionic polymer and the heparin, and grafting of the zwitterionic polymer and the heparin on the surface of the medical material is completed through incubation. The coating provided by the invention has excellent hydrophilicity, can form a hydration layer, provides a physical barrier, and remarkably prevents adhesion and colonization of microorganisms. The inhibition rate of the coating on escherichia coli and staphylococcus aureus exceeds 99%, protein adhesion is remarkably reduced in an anti-protein adhesion experiment, and the coating is simple in strategy design, has a potential application prospect in the aspect of preventing blood contact catheter related infection and thrombosis, and has a wide application prospect. The complication occurrence rate and the medical care cost can be reduced.

The invention discloses photocuring hydrogel capable of being combined with cytokines and used for tumor organoid culture and application, and belongs to the technical field of organoid culture. According to the invention, the hydrogel which can fix cells, can be combined with cell factors and can realize organoid recovery is developed through norbornene modified heparin, norbornene modified gelatin, sulfydryl four-arm polyethylene glycol, glucan, matrix metal protein peptidomimetic MMP and a photoinitiator. The hydrogel can be used for directly preparing organoids, heparin of various structures can be used, the cost is reduced, the modified heparin can bind factors or matrix protein and can controllably release the factors, the modified gelatin provides amino acid energy for collagen hydrolysate, and the hydrogel is formed by photocuring in a stepwise polymerization mode, is controllable in structure and can be used for preparing collagen collagen. The adjustable bionic modulus and the adjustable bionic stress relaxation are realized. The hydrogel disclosed by the invention can be used for culturing various organs, overcomes the problems of low repeatability, instability and the like in the prior art, and is suitable for the fields of tumor drug evaluation and the like.

The invention discloses a heparin impurity detection method and system based on a Raman spectrum. Impurities in heparin production are efficiently detected through a Raman spectrum technology, and a production process is optimized. The method comprises the following steps: firstly, obtaining original Raman spectrum data of a heparin production sample, performing quality analysis, and optimizing data to obtain parameters; extracting spectral data features, and generating a three-dimensional feature matrix; detecting abnormal spectral characteristics by using a density clustering algorithm, identifying impurities, and obtaining impurity detection data; and the impurity change trend is analyzed in combination with production timestamp data, and production process parameters are optimized. According to the method, the impurities can be accurately detected in real time, the production process is dynamically optimized, and the quality and safety of a heparin product are ensured. The system realizes efficient quality control, and has a wide application prospect, especially in the field of biological pharmacy.

The invention relates to the field of medical health and artificial intelligence, and discloses a cancer patient low-molecular heparin individualized dose dynamic optimization method based on reinforcement learning, and the method comprises the steps: S1, collecting multi-dimensional clinical data of a cancer patient, carrying out the preprocessing, carrying out the enhancement of the preprocessed data, and generating time sequence synthesis data; s2, based on the multi-dimensional clinical data and the time sequence synthesis data, constructing a reinforcement learning environment, including defining a state space, an action space and a reward function; s3, constructing an environment adaptive deep reinforcement learning EA-DRL model as a dose optimization model; performing model training and optimization in the reinforcement learning environment until convergence and obtaining an optimal dose decision strategy; and S4, inputting real-time dynamic clinical data of a patient to be decided into the trained dosage optimization model, and outputting individualized low molecular heparin LMWH administration dosage recommendation. Individualized precise administration is realized, and the treatment effect and the clinical medication safety are improved.

The present application belongs to the field of medical device technology, and discloses a blood purification device and an operation method thereof, wherein the device comprises: a mobile trolley, a fixed bracket, a purification mechanism and an abnormal monitoring mechanism; a fixed bracket is provided on the mobile trolley, and a purification mechanism is provided on the fixed bracket; an abnormal monitoring mechanism is fixedly provided on the fixed bracket; the purification mechanism comprises an arterial pot, a dialyzer, a venous pot, a blood pump, a replacement fluid storage box, an ultrafiltrate collection box, a dialysate storage box, a replacement fluid pump, an ultrafiltrate pump, an arterial tube, a venous tube, a dialysate pump and a heparin pump, and a purification capacity evaluation module is fixedly provided on the fixed bracket. The present invention continuously monitors the blood purification process through the abnormal monitoring mechanism, promptly discovers abnormal conditions in the blood purification process, evaluates the dialysis effect of the dialyzer according to the monitoring data, and ensures that when the main dialyzer fails or has problems, the standby dialyzer can be immediately activated by setting two dialyzers, so as to ensure the continuity of the dialysis process and the safety of the patient.

To provide a safe, effective agent for improving skin texture.SOLUTION: It was discovered that a pharmaceutical composition having a polysulfated mucopolysaccharide such as a heparinoid, etc., or a salt thereof as an active ingredient is useful for improving skin texture or reducing a bumpy area.SELECTED DRAWING: Figure 1

The disclosure provides an extracorporeal devices, systems and methods for removing a pathogen or a toxin from a biological fluid of a subject comprising contacting a biological fluid from the subject with a loosely packed bed of adsorption media, such as a fluidized bed, wherein the adsorption media comprises heparin, to remove the pathogen or the toxin to form a treated biological fluid; and infusing the treated fluid into the subject.

The present disclosure relates to a membrane prepared from a blend comprising i) a polysulfone, polyether sulf one or polyarylethersulfone and ii) polyvinylpyrrolidone, characterized in that the membrane is coated with polydopamine and chon-droitin. Optionally the coating further comprises heparin. The disclosure further relates to a process for producing the coated membrane, a method of increasing the selectivity of a membrane, and to a filtration / diffusion device comprising the membrane which can be used, for example, in hemodialysis applications.

The invention relates to the technical field of biological medicine, in particular to a targeting nanoparticle and a preparation method and application thereof. The targeted nano-particle designed and synthesized by the invention comprises a nano-liposome and low-molecular heparin entrapped in the nano-liposome, wherein the surface of the nano-liposome is modified with CREKA peptide. Wherein the CREKA peptide can target fibrinogen in thrombus and specifically recognize FN1 at the thrombus part, so that LMWH is delivered to the thrombus part in a targeted manner, the local antithrombotic effect is improved, meanwhile, the risks of extra bleeding and toxicity are reduced to the maximum extent, and the limitation of traditional LMWH is solved.

The invention discloses a collagen-based and high-transparency matrix for cornea thickening and a preparation method of the collagen-based and high-transparency matrix. The preparation method comprises the following steps: assembling a collagen composite solution into a collagen matrix implant on a set curvature mold through electrochemical deposition; the collagen composite solution is prepared from collagen, glacial acetic acid, hydrogen peroxide, heparin and water; putting the obtained collagen matrix implant and a mold into a cross-linking agent solution for cross-linking; cleaning the residual cross-linking agent after completion, separating the collagen matrix implant from the mold, and placing the collagen matrix implant under an ultraviolet light source for cross-linking to obtain a double-cross-linked collagen matrix implant; and soaking the double-crosslinked collagen matrix implant in a nerve growth factor solution, and performing absorption and combination to obtain the collagen-based and high-transparency matrix for cornea thickening. According to the invention, an electro-deposition assembly technical scheme is adopted, the diameter and thickness of collagen assembly fibers are adjusted and controlled through electric field energy, and the collagen assembly fibers are orderly and regularly arranged, so that scattering and refraction of light are reduced, the light transmittance of cornea is increased and can reach more than 90%, and the problem of light blocking caused by materials is effectively avoided. Operation is matched with femtosecond equipment, operation is easy, consumed time is short, and trauma is small.

The invention belongs to the technical field of perioperative anticoagulation management, and particularly relates to a heparin dose-effect relationship modeling method, a heparin dose-effect relationship prediction system and a storage medium. The modeling method comprises the following steps: inputting clinical data from a single patient, wherein the clinical data comprises the administration dosage of heparin and a corresponding ACT measurement value; fitting different models suitable for the heparin dose-effect relationship based on the clinical data, and selecting an optimal model through cross validation; and re-training the optimal model by adopting all clinical data of a single patient to obtain the optimal model actually used for deployment. The invention also provides a system for predicting the heparin dose-effect relationship by using the model. Compared with a single model for predicting the heparin dosage-effect relationship, the method has higher accuracy, is beneficial to accurately controlling the heparin dosage of a patient, and has a very good application prospect in anticoagulation management in the perioperative period.

The invention discloses a construction method of a heparin 2-O-sulfotransferase high-activity mutant, and belongs to the technical field of biology. According to the heparin 2-O-sulfotransferase and the application of the heparin 2-O-sulfotransferase, a dissolution promoting label is fused at the N end of the heparin 2-O-sulfotransferase, the coding sequence of the dissolution promoting label is optimized, and active expression of the heparin 2-O-sulfotransferase is achieved; according to the invention, the heparin 2-O-sulfotransferase is mutated, so that a mutant with high stability and catalytic activity is obtained; furthermore, fermentation conditions of the heparin 2-O-sulfotransferase are optimized, so that the expression quantity and the enzyme activity are improved, and the application potential of the heparin 2-O-sulfotransferase in industrial production is enhanced.

The invention relates to a heparinized gelatin / sodium alginate pancreas islet packaging material with an anti-fibrosis function as well as a preparation method and application of the heparinized gelatin / sodium alginate pancreas islet packaging material. The preparation method comprises the following steps: adding gelatin into normal saline, soaking, performing autoclaved sterilization to obtain a gelatin solution, then adding epsilon-polylysine hydrochloride into the gelatin solution, and finally adding glutamine transaminase for reaction to obtain an epsilon-polylysine grafted gelatin solution; adding heparin into the solution, and reacting to obtain a heparinized gelatin solution; adding sodium alginate and glutamine transaminase, reacting, diluting, preparing hydrogel microspheres by adopting an electrostatic spraying method, and cross-linking to obtain the hydrogel microspheres. According to the invention, heparin molecules are incorporated into a pancreas islet packaging system, so that fibrosis at the periphery of the microspheres can be relieved, the pancreas islet cells are packaged by using the pancreas islet packaging material to prepare the biological artificial pancreas, the pancreas islet cell proliferation and insulin secretion can be promoted, and the pancreas islet packaging material has a good diabetes treatment effect.

The invention discloses a gel dressing for treating haemorrhoids and a preparation method of the gel dressing. The gel dressing is prepared from the following raw materials in parts by weight: modified chitosan, multifunctional lipidosome, fructo-oligosaccharide, hyaluronic acid, carbomer, glycerol and recombinant human epidermal growth factors. Chitosan has good film-forming property and antibacterial activity, when haemorrhoids are cracked and bleeding due to long-term constipation, a wound surface is in a high-pH and high-ROS environment, the modified chitosan forms a compact protective film on the ulcerated wound surface, the multifunctional lipidosome with contracted film holes and larger particle size is blocked outside, heparin molecules are grafted on the modified chitosan, and the heparin molecules are grafted on the surface of the wound surface. Recombinant human epidermal growth factors are allowed to pass through, and wound healing is accelerated. When the ulceration part is gradually healed, the pH and ROS level return to normal, the protective film of the modified chitosan is expanded, and the multifunctional liposome is diffused and degraded through the protective film to release the pepper extract, the borneol and the menthol. Fructo-oligosaccharide is added to maintain normal flora balance in the anorectum area.

The invention discloses a double-layer small-caliber artificial blood vessel with an in-situ modified anticoagulant coating and a preparation method. The double-layer small-caliber artificial blood vessel with the in-situ modified anticoagulant coating is prepared by combining a coaxial dry-jet wet spinning technology and a polydopamine-heparin modification technology. According to the obtained double-layer small-caliber blood vessel, the outer layer provides enough mechanical strength and structural stability, the inner layer has good hydrophilicity and excellent anticoagulation function through polydopamine in-situ grafting heparin, activation of platelets and adhesion of blood cells are reduced, formation of short-term acute thrombus is prevented, and the endothelialization process of the small-caliber blood vessel is promoted; according to the method provided by the invention, the manufacturing and surface modification process of the small-caliber artificial blood vessel is simplified, additional procedures such as secondary processing are avoided, the modification position and the grafting amount are controllable, the experimental stability is high, and a convenient and efficient preparation technical idea is provided for developing the small-caliber artificial blood vessel.

The invention belongs to the technical field of biology, and discloses a fusion type polypeptide for improving the activity of umbilical cord mesenchymal stem cells and application of the fusion type polypeptide. The amino acid sequence of the fusion type polypeptide provided by the invention is any one sequence as shown in SEQ ID NO.1-3. The fusion type polypeptide is obtained by integrating an extracellular matrix amino acid sequence and a heparin amino acid sequence. The umbilical cord mesenchymal stem cells obtained by culturing the fusion type polypeptide have good multiplication capacity, can promote expression of the Ki67 gene and inhibit aging of the umbilical cord mesenchymal stem cells, and have wide application prospects.

The invention discloses an artificial blood vessel and a preparation method thereof, and the preparation method comprises the following steps: uniformly mixing an erythrocyte ghost suspension and melanin nanoparticles to obtain a mixed solution; carrying out ultrasonic treatment and extrusion on the mixed solution to obtain a melanin nano-vesicle solution; carrying out electrostatic spinning on the polycaprolactone solution to obtain a polycaprolactone electrostatic spinning blood vessel; soaking the polycaprolactone electrostatic spinning blood vessel in an ethylenediamine solution, and then washing the polycaprolactone electrostatic spinning blood vessel with a phosphate buffer solution; then soaking in a 4-morpholine ethanesulfonic acid solution; finally, carrying out heparinization in a 4-morpholine ethanesulfonic acid solution containing 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and heparin; and incubating the heparin-modified polycaprolactone electrostatic spinning blood vessel in the melanin nano-vesicle solution to obtain the artificial blood vessel. The melanin nano-vesicles are modified, so that the anticoagulation performance of erythrocyte membranes is reserved, and meanwhile, the scavenging capacity of melanin nano-particles on reactive oxygen free radicals is reserved.

This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

The present invention discloses a high-precision chip-type micropump wearable precision syringe, which specifically relates to the technical field of medical devices. The present invention evacuates a hydraulic liquid supply tank to a vacuum to form a negative pressure, and then the needle tip of a liquid-filled injection needle pierces a heparin cap, so that the drug driving liquid is pressed into the hydraulic liquid supply tank and squeezes the piston of the pushing unit to move to one side. The volume of the hydraulic liquid supply tank increases, and the drug driving liquid enters the micropump unit through the micropump liquid inlet hole. Since the micropump unit swings to a fixed value each time, the drug driving liquid is accurately driven and controlled, and the injection volume is accurately controlled. The piston member in the cartridge bottle is pushed forward to quantitatively push the injection liquid, and the liquid drives the liquid, so that the infusion is accurate and reliable; the implanted spring pushes the indwelling needle catheter seat to be clamped into the convex ring cavity. Afterwards, the stainless steel needle is withdrawn, leaving only the soft indwelling needle catheter in the blood vessel. Injection is performed through the indwelling needle catheter without waiting for too long, thereby reducing the discomfort and pain caused to the patient.

The hemodialysis device comprises a dialysis equipment body, a dialysate tank and a waste liquid tank, a dialyzer, a blood pump and a heparin pump are arranged on the outer side of the dialysis equipment body, and the top and the bottom of the dialyzer communicate with an arterial communicating pipe and a venous communicating pipe correspondingly; the lower portion and the upper portion of the dialyzer are communicated with a dialysate inlet pipe and a waste liquid discharge pipe respectively, a groove is formed in the dialysis equipment body, the blood pump comprises a driving motor, a sliding groove is formed in the outer portion of the dialysis equipment body, and a pushing plate is jointly slidably connected into the groove and the sliding groove. And a linkage mechanism is arranged between the pushing plate and the output shaft of the driving motor. When the blood pump is started to enable blood in the body of a patient to enter the dialysate tank through the arterial communicating pipe to be purified, the push plate can slowly push the piston rod upwards to squeeze a heparin agent in the cylinder into the arterial communicating pipe; and the supply amount of the heparin agent can be automatically adjusted according to the flow of blood entering the arterial communicating pipe.

A chitosan-heparin nanomotor and a method for producing same are disclosed. A STING agonist-encapsulated urease-based chitosan-heparin nanomotor delivers the STING agonist directly to bladder mucosal cells in the bladder, and thus can induce an immune response.

The utility model discloses CRRT equipment, and relates to the technical field of medical instruments. The CRRT equipment comprises a plurality of functional modules, and each functional module is provided with an independent control display unit and an independent driving pump and can independently realize respective functions. Each function module is relatively small in size, small in occupied space and convenient to carry and place in special scenes such as an ambulance, a mountain top disaster relief area, a battlefield first-line, a ship and a warship for use. The heparin pump module, the dialysate pump module, the displacement liquid pump module, the blood pump module and the waste liquid pump module can be independently used as independent modules and can also be used in a combined mode. During combined use, the heparin pump module, the dialysate pump module, the displacement liquid pump module and the waste liquid pump module are all in communication connection with the blood pump module and are used for blood purification treatment; when the medical transfusion bag is independently used, various requirements of emergency blood transfusion, transfusion and nutrition delivery in special scenes such as ambulances, mountain top disaster relief areas, first-line battlefields, ships, warships and the like can be met.

This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.

The present disclosure relates to a stable human platelet lysate composition; preferably a stable heparin-free human platelet lysate composition; methods for obtaining said composition and uses thereof.

The invention belongs to the field of biomedical materials and tissue engineering, and particularly relates to an injectable mineralized collagen bone repair composite material loaded with stem cell recruitment factors and osteogenic induction factors and a preparation method of the injectable mineralized collagen bone repair composite material. The composite material is composed of 50%-53% of mineralized collagen matrix particles, 15%-20% of SDF-1alpha loaded heparinized gelatin microspheres, 15%-20% of BMP-2 loaded PDA coated mesoporous silica particles, 8%-10% of an NHS-PEG-NHS cross-linking agent and 4%-6% of glycerin. The composite material can realize time-space sequential regulation and control of'collection first and then differentiation '; a bionic bone matrix microenvironment is provided through the mineralized collagen matrix; the problems of two-factor release conflict and stability are solved; in-vitro experiments show that the material can significantly promote stem cell migration and osteogenic differentiation, and animal experiments prove that the material can recover 82-88% of mechanical properties of bone defect parts. The invention solves the technical problems of insufficient stem cell collection, low osteogenic differentiation efficiency and uncontrollable factor release of the existing bone repair material.

The invention belongs to the technical field of medical instruments, and provides a painless microneedle patch loaded with low-molecular-weight heparin and a preparation method of the painless microneedle patch in order to solve the problems that most existing microneedle products aim at small-molecular drugs, lack protection and slow release design for the low-molecular-weight heparin, low drug loading efficiency, poor activity retention and incapability of adapting to long-term anticoagulation treatment. The painless micro-needle patch comprises a substrate layer and a composite micro-needle, the composite microneedle is composed of a plurality of microneedles arranged in an array and fixed on one surface of the substrate layer and a low-molecular heparin delivery material loaded in the microneedles. According to the painless microneedle patch loaded with the low-molecular heparin, efficient percutaneous delivery of drugs can be achieved, local adverse reactions are reduced, the operation process is simplified, and the long-term drug use requirements under different anticoagulation scenes are met.

The invention discloses double-network hydrogel based on chlorogenic acid as well as a preparation method and application of the double-network hydrogel, and belongs to the technical field of wound dressings. A first network of the double-network hydrogel based on the chlorogenic acid is formed by coordination of the chlorogenic acid and Zn < 2 + >, and CA and Zn < 2 + > can be quickly released in inflammation and proliferation stages, so that the effects of resisting bacteria, resisting oxidation, diminishing inflammation and generating blood vessels are achieved; the second network is formed by covalent crosslinking of heparin grafted gelatin and genipin, crosslinking of gelatin and genipin can enhance the mechanical strength, heparin is grafted into gelatin, bFGF can be stably added, the release time of bFGF at a wound part can be prolonged, and bFGF is slowly released in proliferation and remodeling stages, so that scars are prevented from being formed; in-vivo studies of MRSA infected diabetic mouse models and rabbit ear hyperplastic scar models show that the dual-network hydrogel can significantly promote healing of scar-free wounds. The programmed release function of the CZGF hydrogel plays a key role in accelerating chronic wound healing and preventing scar formation.

The invention relates to the technical field of blood purification, in particular to an anticoagulation pump which comprises a bottom plate, an injection pushing mechanism and a liquid medicine feeding mechanism, a hemodialysis machine is fixedly installed on the upper side of the bottom plate, a blood drawing pipe is fixedly arranged on one side of the hemodialysis machine, and an infusion tube is fixedly arranged on the other side of the hemodialysis machine; a round seat frame and a box body are fixedly connected to the upper side of the bottom plate, an injector is clamped in the round seat frame, heparin can be supplemented to the injector through the injection pushing mechanism, the injector, the box body and a piston rod, heparin can be continuously injected, blood is prevented from being coagulated in the hemodialysis machine, and the hemodialysis efficiency is improved. The hemodialysis purification device has the advantages that smooth flow of blood is guaranteed, the injector does not need to be replaced, time and labor are saved during operation, long-time interruption of heparin injection is avoided, improvement of the anticoagulation effect of hemodialysis purification is facilitated, the hemodialysis purification process can be smoothly performed, and meanwhile, the working efficiency of the anticoagulation pump is improved.